Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA reform bill in Senate would ship slow NDA reviews to outside groups.

This article was originally published in The Tan Sheet

Executive Summary

FDA EFFICIENCY WOULD BE ENFORCED BY TAKING SLOW REVIEWS AWAY from the agency and delegating them to outside third-party groups in the first version of FDA reform legislative language from Sen. Nancy Kassebaum (R-Kan.). Under a discussion draft released by the Kansas Republican on Nov. 3, FDA would be given roughly four years to eliminate backlogs within its product review divisions and come into compliance with all review deadlines.
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS084454

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel